TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
收藏NIAID Data Ecosystem2026-03-11 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2346653
下载链接
链接失效反馈官方服务：
资源简介：
TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizumab (PD-1 inhibitor) or cetuximab (EGFR inhibitor) in patients with advanced refractory / resistant solid malignancies.
The study is enrolling in the dose expansion arms.
创建时间：
2020-07-15
